FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2579134619> ?p ?o ?g. }

• W2579134619 abstract "Background Tramadol is an opioid analgesic licensed for use in moderate to severe pain. It is considered as a low risk for abuse, so control regulations are not as stringent as for 'strong' opioids such as morphine. It has a potential role as a step 2 option of the World Health Organization (WHO) analgesic ladder. Objectives To assess the benefits and adverse effects of tramadol with or without paracetamol (acetaminophen) for cancer‐related pain. Search methods We searched the following databases using a wide range of search terms: the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, and LILACS. We also searched three clinical trials registry databases. The date of the last search was 2 November 2016. Selection criteria We selected studies that were randomised, with placebo or active controls, or both, and included a minimum of 10 participants per treatment arm. We were interested particularly in blinded studies, but also included open studies. We excluded non‐randomised studies, studies of experimental pain, case reports, and clinical observations. Data collection and analysis Two review authors independently extracted data using a standard form and checked for agreement before entry into Review Manager 5. We included information about the number of participants treated and demographic details, type of cancer, drug and dosing regimen, study design (placebo or active control) and methods, study duration and follow‐up, analgesic outcome measures and results, withdrawals, and adverse events. We collated multiple reports of the same study, so that each study, rather than each report, was the unit of interest in the review. We assessed the evidence using GRADE and created a 'Summary of findings' table. The main outcomes of interest for benefit were pain reduction of 30% or greater and 50% or greater from baseline, participants with pain no worse than mild, and participants feeling much improved or very much improved. Main results We included 10 studies (12 reports) with 958 adult participants. All the studies enrolled participants with chronic malignant tumour‐related pain who were experiencing pain intensities described as moderate to severe, with most experiencing at least 4/10 with current treatment. The mean ages were 59 to 70 years, with participants aged between 24 and 87 years. Study length ranged from one day to six months. Five studies used a cross‐over design. Tramadol doses ranged from 50 mg as single dose to 600 mg per day; doses of 300 mg per day to 400 mg per day were most common. Nine studies were at high risk of bias for one to four criteria (only one high risk of bias for size). We judged all the results to be very low quality evidence because of widespread lack of blinding of outcome assessment, inadequately described sequence generation, allocation concealment, and small numbers of participants and events. Important outcomes were poorly reported. There were eight different active comparators and one comparison with placebo. There was little information available for any comparison and no firm conclusions could be drawn for any outcome. Single comparisons of oral tramadol with codeine plus paracetamol, of dihydrocodeine, and of rectal versus oral tramadol provided no data for key outcomes. One study used tramadol combined with paracetamol; four participants received this intervention. One study compared tramadol with flupirtine ‐ a drug that is no longer available. One study compared tramadol with placebo and a combination of cobrotoxin, tramadol, and ibuprofen, but the dosing schedule poorly explained. Two studies (191 participants) compared tramadol with buprenorphine. One study (131 participants) reported a similar proportion of no or mild pain at 14 days. Three studies (300 participants) compared tramadol with morphine. Only one study, combining tramadol, tramadol plus paracetamol, and paracetamol plus codeine as a single weak‐opioid group reported results. Weak opioid produced reduction in pain of at least 30% from baseline in 55/117 (47%) participants, compared with 91/110 (82%) participants with morphine. Weak opioid produced reduction in pain of at least 50% in 49/117 (42%) participants, compared with 83/110 (75%) participants with morphine. There was no useful information for any other outcome of benefit or harm. Authors' conclusions There is limited, very low quality, evidence from randomised controlled trials that tramadol produced pain relief in some adults with pain due to cancer and no evidence at all for children. There is very low quality evidence that it is not as effective as morphine. This review does not provide a reliable indication of the likely effect. The likelihood that the effect will be substantially different is very high. The place of tramadol in managing cancer pain and its role as step 2 of the WHO analgesic ladder is unclear." @default.
• W2579134619 created "2017-01-26" @default.
• W2579134619 creator A5029049881 @default.
• W2579134619 creator A5038998860 @default.
• W2579134619 creator A5077191679 @default.
• W2579134619 date "2017-05-16" @default.
• W2579134619 modified "2023-09-30" @default.
• W2579134619 title "Tramadol with or without paracetamol (acetaminophen) for cancer pain" @default.
• W2579134619 cites W135125595 @default.
• W2579134619 cites W1481128086 @default.
• W2579134619 cites W1492190510 @default.
• W2579134619 cites W1504991804 @default.
• W2579134619 cites W1643932754 @default.
• W2579134619 cites W1729003160 @default.
• W2579134619 cites W1817199972 @default.
• W2579134619 cites W1895160223 @default.
• W2579134619 cites W1895694701 @default.
• W2579134619 cites W1903244100 @default.
• W2579134619 cites W1917158670 @default.
• W2579134619 cites W1924243490 @default.
• W2579134619 cites W1964560684 @default.
• W2579134619 cites W1979762189 @default.
• W2579134619 cites W1982924223 @default.
• W2579134619 cites W1995021873 @default.
• W2579134619 cites W2007440728 @default.
• W2579134619 cites W2009494217 @default.
• W2579134619 cites W2015824469 @default.
• W2579134619 cites W2019968234 @default.
• W2579134619 cites W2024820523 @default.
• W2579134619 cites W2029133283 @default.
• W2579134619 cites W2045730050 @default.
• W2579134619 cites W2047586716 @default.
• W2579134619 cites W2050392186 @default.
• W2579134619 cites W2063738853 @default.
• W2579134619 cites W2072380646 @default.
• W2579134619 cites W2077944993 @default.
• W2579134619 cites W2093043874 @default.
• W2579134619 cites W2093706445 @default.
• W2579134619 cites W2093914955 @default.
• W2579134619 cites W2103600429 @default.
• W2579134619 cites W2107021177 @default.
• W2579134619 cites W2108868101 @default.
• W2579134619 cites W2116446898 @default.
• W2579134619 cites W2120686611 @default.
• W2579134619 cites W2123657472 @default.
• W2579134619 cites W2127461273 @default.
• W2579134619 cites W2129725155 @default.
• W2579134619 cites W2152050780 @default.
• W2579134619 cites W2161344815 @default.
• W2579134619 cites W2162296777 @default.
• W2579134619 cites W2189982580 @default.
• W2579134619 cites W2235570983 @default.
• W2579134619 cites W2248465572 @default.
• W2579134619 cites W2273842610 @default.
• W2579134619 cites W2282584290 @default.
• W2579134619 cites W2337210803 @default.
• W2579134619 cites W2468992771 @default.
• W2579134619 cites W2593926725 @default.
• W2579134619 cites W2600954565 @default.
• W2579134619 cites W4211155124 @default.
• W2579134619 cites W4254679892 @default.
• W2579134619 cites W4294215472 @default.
• W2579134619 cites W4319054171 @default.
• W2579134619 cites W4322703438 @default.
• W2579134619 cites W2595437246 @default.
• W2579134619 doi "https://doi.org/10.1002/14651858.cd012508.pub2" @default.
• W2579134619 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6481722" @default.
• W2579134619 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28510996" @default.
• W2579134619 hasPublicationYear "2017" @default.
• W2579134619 type Work @default.
• W2579134619 sameAs 2579134619 @default.
• W2579134619 citedByCount "26" @default.
• W2579134619 countsByYear W25791346192017 @default.
• W2579134619 countsByYear W25791346192018 @default.
• W2579134619 countsByYear W25791346192019 @default.
• W2579134619 countsByYear W25791346192020 @default.
• W2579134619 countsByYear W25791346192021 @default.
• W2579134619 countsByYear W25791346192022 @default.
• W2579134619 countsByYear W25791346192023 @default.
• W2579134619 crossrefType "journal-article" @default.
• W2579134619 hasAuthorship W2579134619A5029049881 @default.
• W2579134619 hasAuthorship W2579134619A5038998860 @default.
• W2579134619 hasAuthorship W2579134619A5077191679 @default.
• W2579134619 hasBestOaLocation W25791346192 @default.
• W2579134619 hasConcept C121608353 @default.
• W2579134619 hasConcept C126322002 @default.
• W2579134619 hasConcept C141071460 @default.
• W2579134619 hasConcept C142724271 @default.
• W2579134619 hasConcept C170493617 @default.
• W2579134619 hasConcept C17744445 @default.
• W2579134619 hasConcept C177713679 @default.
• W2579134619 hasConcept C1862650 @default.
• W2579134619 hasConcept C197934379 @default.
• W2579134619 hasConcept C199539241 @default.
• W2579134619 hasConcept C204787440 @default.
• W2579134619 hasConcept C27081682 @default.
• W2579134619 hasConcept C2777288759 @default.
• W2579134619 hasConcept C2778722691 @default.
• W2579134619 hasConcept C2778904085 @default.
• W2579134619 hasConcept C2779473830 @default.

• next